JP4643936B2 - 血栓症改善剤 - Google Patents
血栓症改善剤 Download PDFInfo
- Publication number
- JP4643936B2 JP4643936B2 JP2004212422A JP2004212422A JP4643936B2 JP 4643936 B2 JP4643936 B2 JP 4643936B2 JP 2004212422 A JP2004212422 A JP 2004212422A JP 2004212422 A JP2004212422 A JP 2004212422A JP 4643936 B2 JP4643936 B2 JP 4643936B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- ganoderma
- black
- thrombosis
- red
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000007536 Thrombosis Diseases 0.000 title claims description 17
- 241000222336 Ganoderma Species 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012264 purified product Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 240000008397 Ganoderma lucidum Species 0.000 claims description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims 1
- 238000007670 refining Methods 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000002785 anti-thrombosis Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002834 transmittance Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000134916 Amanita Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000906988 Ganoderma atrum Species 0.000 description 1
- 241001489090 Ganoderma japonicum Species 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- -1 sorbit Chemical compound 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
例えば、心臓や脳の血管に血栓が形成されると、心筋梗塞、脳梗塞を引き起こし、生命に危険をもたらす。また、重度の血栓ではなくても、正常状態よりも血栓の量が増加すると、動脈硬化、痴呆、血圧異常、めまい、肩こり、頭痛、腰痛、関節痛、目のかすみ、不眠、動悸、息切れ、血圧異常、不整脈などの症状を引き起こす。また、その他に血流の悪化によって起こりうる、くすみ、くまなどの症状も引き起こす。
赤霊芝子実体の乾燥物100gに精製水2Lを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して赤霊芝の水抽出物を6.0g得た。
黒霊芝子実体の乾燥物1.5Kgにエタノール20Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、黒霊芝のエタノール抽出物を30g得た。
製造例2の黒霊芝のエタノール抽出物2.0gをエタノール350mLに溶解し、同容量の精製水とヘキサンを加えて抽出した。水層部分を1/2に濃縮し、同容量の酢酸エチルを加えて抽出した後、濃縮乾固し、酢酸エチル画分0.56gを得た。
文献(嘉久志寿人,四家勉,早崎洋子,松原尚志,内田清久,本間義春,川角浩,竹内良夫,日本薬理学雑誌,Vol.95,335−346,1990、Born,G.V.R.,Nature,Vol.194,927−929,1962)を参考に行った。
エーテル麻酔下でモルモットの心臓より3.8%クエン酸ナトリウム1容に対し血液9容の割合で採血し、室温で1,000rpm、15分遠心後上清を採取し多血小板血漿(Platelet−Rich Plasma:PRP)とした。残りの血液は室温で3,000rpm、15分遠心し乏血小板血漿(Platelet−Poor Plasma:PPP)を得、PRPとPPPを等量混合したもの(A液とする)を試験に用いた。
血小板凝集反応はBornの方法に準じて、血小板凝集計(NBS HEMA TRACER 601、二光バイオサイエンス)を用いて測定した。すなわちA液180マイクロLに試験試料溶液20マイクロLを加え、37℃で1分間撹拌(1,000rpm)予備加熱後血小板凝集惹起物質(ADP)22マイクロLを添加し、血小板の凝集により生じた透光度の変化を経時的に記録した。血小板の凝集率はPRP及びPPPの透光度をそれぞれ0%及び100%とし、凝集剤添加後の最大透光度を最大凝集率とした。血小板凝集阻害率は以下の式で算出した。
血小板凝集阻害率(%)={1−(凝集剤添加後の最大透光度)/(凝集剤添加前の最大透光度)}×100
併用効果(倍)=(赤霊芝の水抽出物と黒霊芝の溶媒分画精製物の併用による血小板凝集阻害率)/{(赤霊芝の水抽出物による血小板凝集阻害率)+(黒霊芝の溶媒分画精製物による血小板凝集阻害率)}
Claims (1)
- 赤霊芝の水抽出物及び黒霊芝の溶媒分画精製物を含有することを特徴とする血栓症改善剤。ただし、黒霊芝の溶媒分画精製物は、次の方法で製造する。
黒霊芝のエタノール抽出物のエタノール溶液に、精製水とヘキサンを加えて抽出し、その水層に酢酸エチルを加えて抽出した後、酢酸エチル層を濃縮乾固して得られたものを黒霊芝の溶媒分画精製物とする。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004212422A JP4643936B2 (ja) | 2004-07-21 | 2004-07-21 | 血栓症改善剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004212422A JP4643936B2 (ja) | 2004-07-21 | 2004-07-21 | 血栓症改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006028128A JP2006028128A (ja) | 2006-02-02 |
JP4643936B2 true JP4643936B2 (ja) | 2011-03-02 |
Family
ID=35894899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004212422A Expired - Lifetime JP4643936B2 (ja) | 2004-07-21 | 2004-07-21 | 血栓症改善剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4643936B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160012600A (ko) * | 2014-07-24 | 2016-02-03 | 주식회사 사임당화장품 | 지실 추출물을 유효성분으로 함유하는 혈전용해용 조성물 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101078306B1 (ko) * | 2009-04-17 | 2011-10-31 | (주)에이치케이바이오텍 | 나토균 배양물과 버섯균 배양물이 포함된 혈전 용해용 조성물 |
JP2012131754A (ja) * | 2010-12-24 | 2012-07-12 | Nippon Menaade Keshohin Kk | 抗血栓剤 |
JP5864186B2 (ja) * | 2011-09-29 | 2016-02-17 | 日本メナード化粧品株式会社 | 発毛促進剤 |
JP2016056140A (ja) * | 2014-09-11 | 2016-04-21 | 日本メナード化粧品株式会社 | 概日リズム調整剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57112331A (en) * | 1980-12-29 | 1982-07-13 | Toyo Yakushiyoku Kogyo Kk | Medical composition of ganoderma lucidum component |
JPS62239953A (ja) * | 1986-04-11 | 1987-10-20 | Yasahiro Morita | 霊芝茶の製造法 |
JP2001187745A (ja) * | 1999-12-28 | 2001-07-10 | Joyaku Kenkyusho:Kk | 霊芝生理活性エキスおよびそれを用いる健康食品 |
JP2003063981A (ja) * | 2001-08-29 | 2003-03-05 | Nonogawa Shoji Kk | 滋養強壮剤 |
JP2003104904A (ja) * | 2001-09-28 | 2003-04-09 | Nonogawa Shoji Kk | 高血圧抑制剤 |
-
2004
- 2004-07-21 JP JP2004212422A patent/JP4643936B2/ja not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57112331A (en) * | 1980-12-29 | 1982-07-13 | Toyo Yakushiyoku Kogyo Kk | Medical composition of ganoderma lucidum component |
JPS62239953A (ja) * | 1986-04-11 | 1987-10-20 | Yasahiro Morita | 霊芝茶の製造法 |
JP2001187745A (ja) * | 1999-12-28 | 2001-07-10 | Joyaku Kenkyusho:Kk | 霊芝生理活性エキスおよびそれを用いる健康食品 |
JP2003063981A (ja) * | 2001-08-29 | 2003-03-05 | Nonogawa Shoji Kk | 滋養強壮剤 |
JP2003104904A (ja) * | 2001-09-28 | 2003-04-09 | Nonogawa Shoji Kk | 高血圧抑制剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160012600A (ko) * | 2014-07-24 | 2016-02-03 | 주식회사 사임당화장품 | 지실 추출물을 유효성분으로 함유하는 혈전용해용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP2006028128A (ja) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6187314B1 (en) | Ginkgo biloba composition method to prepare the same and uses thereof | |
JP5410683B2 (ja) | カンカニクジュヨウから得られる肝保護剤及び抗TNF−α作用剤 | |
CA1337125C (en) | Process for the preparation of isosilybin-free silibinin and pharmaceutical compositions containing it | |
WO2018010332A1 (zh) | 7-羟基-丁苯酞的医药用途 | |
JP2012131754A (ja) | 抗血栓剤 | |
KR20100042414A (ko) | 오매 추출물 또는 이의 분획물을 유효성분으로 함유하는 혈행개선 조성물 | |
JP5085120B2 (ja) | 脳機能改善剤 | |
EP2051721A1 (en) | Preparation and pharmaceutical use of euterpe oleracea (acai) extract compositions | |
JP4643936B2 (ja) | 血栓症改善剤 | |
DE3782430T2 (de) | Verwendung eines trypsininhibitors des kunitztyps aus sojabohnen und seiner derivate zur herstellung von medikamenten und denselben enthaltendes agens. | |
JPH07258103A (ja) | 抗血栓剤及びその製造方法 | |
JP7317309B2 (ja) | オートファジー性細胞死誘導剤 | |
US7485328B2 (en) | Composition for preventing atherosclerosis | |
JP6042500B2 (ja) | 抗血栓剤 | |
EP2124980A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
JP5415108B2 (ja) | Ldlレセプター合成促進剤 | |
JP4536360B2 (ja) | 抗血栓剤 | |
JP4720086B2 (ja) | 動脈硬化予防用組成物 | |
JP2006022033A (ja) | 血管新生抑制剤 | |
JP3958502B2 (ja) | アポトーシスを誘導する新規多糖およびその用途 | |
EA022250B1 (ru) | Способ получения обогащенного экстракта из листьев растения vitis vinifera l. | |
JP3936245B2 (ja) | 血圧降下剤 | |
JPS6045529A (ja) | 抗血栓症剤 | |
EP4059509A1 (en) | Agrimonia eupatoria extract preparation method, and composition for improving liver functions or treating liver diseases, containing extract | |
JPH0733672A (ja) | 動脈硬化抑制剤及びこれを含有する組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101027 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101130 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4643936 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131210 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |